Research programme: neurological disease therapeutics - Q-State Biosciences/Vertex Pharmaceuticals
Latest Information Update: 28 May 2022
At a glance
- Originator Q-State Biosciences; Vertex Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Neurological-disorders in USA
- 04 Apr 2018 Q-State Biosciences and Vertex Pharmaceuticals enter into a drug discovery collaboration agreement to develop therapeutics for the treatment of neurological disorders
- 04 Apr 2018 Early research in Neurological disorders in USA (unspecified route)